Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Zeng, Haoyu  [Clear All Filters]
2024
Wang J, Zeng H, Dong G, Waddell S, McCauley J, Lagrutta A. . J Pharmacol Exp Ther. 2024.
Lin X, Guan T, Li Y, Lin Y, Huang G, Lin Y, Sun P, Li C, Gu J, Zeng H, et al. Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma. Front Immunol. 2024;15:1337557.
Lin X, Guan T, Xu Y, Li Y, Lin Y, Chen S, Chen Y, Wei X, Li D, Cui Y, et al. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma. Front Immunol. 2024;15:1337489.
2023
Chen P, Lin Y, Lin W, Li Y, Fu T, Liu Y, Guan T, Xin M, Ye L, Wang P, et al. Human dental pulp stem cells have comparable abilities to umbilical cord mesenchymal stem/stromal cells in regulating inflammation and ameliorating hepatic fibrosis. Hum Cell. 2023.
Yang M, Guan T, Chen C-F, He L-F, Wu H-M, Zhang R-D, Li Y, Lin Y-C, Zeng H, Wu J-D. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models. J Immunother. 2023.
2022
Chen J, Huang S, Li H, Li Y, Zeng H, Hu J, Lin Y, Cai H, Deng P, Song T, et al. STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration. Clin Transl Oncol. 2022.
2019
Zeng H, Wang J, Clouse H, Lagrutta A, Sannajust F. HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges. J Pharmacol Toxicol Methods. 2019:106598.
2018
Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HRong, Kraushaar U, Zeng H, et al. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Rep. 2018;24(13):3582-3592.